Resolve BioSciences
Resolve BioSciences is a German spatial biology company commercializing its Molecular Cartography platform — a single-molecule FISH system for multi-modal tissue profiling of RNA, protein, and morphology — serving pharmaceutical companies, academic research institutions, and clinical laboratories in oncology and therapeutics development.
- Company typePrivate
- Founded2020
- HeadquartersDüsseldorf, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Resolve BioSciences does
Resolve BioSciences GmbH is a German life-sciences company founded in 2020 and headquartered in Monheim am Rhein that develops and commercializes Molecular Cartography, a spatial biology platform for high-resolution, multi-modal tissue analysis. The company serves pharmaceutical companies, academic research institutions, and clinical laboratories working in oncology, immuno-oncology, neurology, developmental biology, and therapeutics development, with peer-reviewed adoption documented in Nature, Cell, and Nature Biotechnology publications between 2022 and 2025.
The core technology is a single-molecule fluorescence in situ hybridization (smFISH) workflow with combinatorial labeling that enables detection of up to 330 RNA targets per tissue section on fresh-frozen or FFPE samples without tissue clearing or signal amplification. The product surface spans the MC1 and MC2 benchtop instrumentation platforms, a cyclic immuno-fluorescence protein assay capable of detecting over 10 protein markers per sample, and a software stack comprising ReCognize (web-based 3D expression visualization with cloud-based Seurat clustering and UMAP analysis) and Panel Design Studio (a tool for designing custom gene panels against the Human Protein Atlas). Cell boundary delineation is performed using deep-learning segmentation applied to targeted nuclear, cytoplasmic, and membrane staining.
Resolve Biosciences operates a direct, enterprise-focused go-to-market through an account-registered customer portal (my.resolvebiosciences.com) and an inside/field sales motion, monetizing Molecular Cartography services together with subscription-based access to ReCognize and related data-analysis tools. The company has raised over $100 million in venture capital, anchored by a $71 million Series B led by Patient Square Capital in October 2022, with additional backing from PS Capital Management, Alafi Capital, NRW.Venture, HTGF, Norgine, CD-Venture, NRW.Bank, and Enterprise Singapore. The company is led by CEO and Managing Director Dr. Axel Heinemann, with a leadership team spanning CTO (Dr. Markus Zumbansen), COO (Dr. Peter Grünefeld), CFO (Marko Labus), and CPO (Meike Bongers), and Peer Schatz (PS Capital) as Chairman.
Resolve BioSciences firmographics
Firmographics- Name
- Resolve BioSciences
- Legal name
- Resolve BioSciences GmbH
- Website
- https://resolvebiosciences.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Resolve BioSciences is a German spatial biology company commercializing its Molecular Cartography platform — a single-molecule FISH system for multi-modal tissue profiling of RNA, protein, and morphology — serving pharmaceutical companies, academic research institutions, and clinical laboratories in oncology and therapeutics development.
- Ownership category
- akta.pro rank
Resolve BioSciences industry classification
Industry- Product category
- Spatial Biology / Spatial Transcriptomics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
- akta.pro secondary industries
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
Keywords
Where Resolve BioSciences is headquartered
LocationHeadquarters
- HQ city
- Düsseldorf
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Resolve BioSciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Molecular Cartography Platform Services: Revenue generated from providing spatial biology analysis services using the Molecular Cartography platform, including RNA and protein assays, data visualization, and support services for research and clinical applications
- Software and Data Analysis Tools: Access to cloud-based data analysis and visualization tools including ReCognize platform for spatial transcriptomics data analysis
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Customer accounts with registration required |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Resolve BioSciences product offering
Product offeringCore offering
Resolve BioSciences delivers a Molecular Cartography™ spatial biology platform built on single-molecule fluorescence in situ hybridization (smFISH), enabling high-resolution, multi-modal profiling of RNA (up to 330 targets), protein (10+ markers), and H&E morphology on the same tissue section without tissue clearing or signal amplification. Offerings include the MC1 and MC2 benchtop instruments, RNA and protein assays, deep learning–based cell segmentation, the ReCognize cloud-based 3D visualization application, and the Panel Design Studio for custom gene panel creation. The company provides these capabilities primarily as fee-for-service spatial biology analysis and through subscription access to its software tools for life sciences researchers and pharmaceutical developers.
Product overview
Resolve BioSciences offers Molecular Cartography, a spatial biology platform comprising hardware instruments (MC1 and MC2 benchtop platforms) and a suite of complementary software tools. The platform is built on single-molecule fluorescence in situ hybridization (smFISH) and provides multi-modal profiling of RNA, protein, and morphology on the same tissue section. Software offerings include ReCognize for 3D data visualization and cloud-based single-cell analysis, and Panel Design Studio for custom gene panel creation. The company was founded in 2020 and is headquartered in Monheim am Rhein, Germany.
Differentiator
Problem solved
Functional benefit
Brands
- Molecular Cartography™: The company's core technology platform for multi-modal spatial profiling with unparalleled sensitivity and specificity, providing true single-molecule RNA fluorescence in situ hybridization for spatial biology analysis.
- ReCognize
Products and services
- Molecular Cartography A spatial biology platform based on single-molecule fluorescence in situ hybridization (smFISH) that delivers high-resolution, multi-modal tissue analysis for disease pathology, neurology, oncology, and developmental biology research. Supports simultaneous profiling of RNA (up to 330 targets), protein (over 10 markers), and morphology (H&E) on the same tissue section without tissue clearing or signal amplification; intended for research institutions, pharmaceutical companies, and academic laboratories.
- MC1 Benchtop Platform First-generation benchtop instrument of the Molecular Cartography platform for spatial molecular imaging, performing targeted RNA and protein assays on tissue samples with high sensitivity and specificity. Used by research institutions, pharmaceutical companies, and academic laboratories performing spatial biology experiments.
- MC2 Next-Generation Benchtop Platform Next-generation benchtop instrument of the Molecular Cartography platform offering expanded scanning area, increased plexity, targeted panel content, advanced controls, and true multi-modality compared to MC1. Designed for next-generation pathology workflows in research and translational settings.
- ReCognize Web-based, all-in-one data visualization and analysis application for Molecular Cartography data. Browses expression data in 3D, automatically builds cell-by-gene expression matrices from uploaded ROI files, performs cell clustering via Seurat in the cloud, generates UMAP visualizations, heatmaps, and exports annotated images and CSV transcript counts. Accessed by registered customers through the My Resolve portal.
- Panel Design Studio Web-based design tool within the My Resolve portal for building custom gene panels by selecting genes, defining probe-sets, and simulating theoretical expression levels across human tissues and cell types using data from The Human Protein Atlas. Used by researchers designing Molecular Cartography RNA experiments.
- Molecular Cartography RNA Assay Spatial transcriptomics assay that uses in-silico designed probes and combinatorial labeling across multiple rounds of hybridization and imaging to detect up to 330 RNA targets per tissue section at subcellular resolution, applied in tumor biology, neurology, and developmental biology research.
- Molecular Cartography Protein Assay Cyclic immuno-fluorescence workflow detecting over 10 protein markers per sample, complementing RNA data for multi-omic analysis ranging from investigational to routine clinical applications, applied in tumor pathology and immuno-oncology research.
Quantifiable outcome
- Detection of up to 330 RNA targets per tissue section in single run
- +2 more outcomes
Companies that use Resolve BioSciences
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Resolve BioSciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature8 records
Resolve BioSciences partnerships and signals
Strategic signalScale indicators6 records
Recent moves5 records
Expansion highlights5 records
Resolve BioSciences competitors and assessment
Company assessmentDirect peers
- 10x Genomics: Direct competitor in spatial biology with Xenium (in situ) and Visium (capture-based) platforms; serves overlapping pharma and academic customers and is the most commercially entrenched player in the spatial transcriptomics market.
- NanoString Technologies: Direct competitor offering GeoMx digital spatial profiling and cosMx high-plex in situ platform; targets the same oncology, immuno-oncology, and translational research customer base as Resolve.
- Vizgen: Direct competitor based on MERFISH technology for high-plex spatial transcriptomics; competes head-to-head with Resolve's Molecular Cartography in academic and pharma research accounts.
- Akoya Biosciences: Direct competitor in spatial biology offering the PhenoCycler (CODEX) and PhenoImager platforms for multiplexed protein and RNA spatial analysis; serves overlapping translational and pharma customers.
Emerging players
- Rebus Biosystems: Emerging spatial transcriptomics player offering the Rebus Esper instrument with a focus on high-plex, single-cell-resolution spatial RNA profiling; competes with Resolve in research-use accounts.
- Singular Genomics: Emerging spatial biology and multi-omics platform player with the G4 sequencing platform and spatial initiatives; partial overlap with Resolve in spatial transcriptomics-adjacent workflows.
Broad incumbents
- Bio-Techne: Broader life-science tools incumbent with RNAscope in situ hybridization technology and a portfolio spanning reagents, instruments, and spatial biology assets (including acquired brands); competes with Resolve in the spatial RNA workflow layer.
- Bruker: Diversified scientific instrument maker that has expanded into spatial biology through acquisitions (e.g., NanoString's spatial assets); competes with Resolve as a broad incumbent entering the spatial transcriptomics market.
- Standard BioTools: Life-science tools company with mass cytometry and spatial biology offerings; less direct overlap but competes for the same translational and pharma research budgets as Resolve.
- Illumina: Sequencing giant with downstream spatial-adjacent offerings (e.g., partnerships and DRAGEN software for spatial data); represents both a potential partner and a competitive threat given its reach into pharma genomic workflows.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Resolve BioSciences social profiles
Digital presenceResolve BioSciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Resolve BioSciences leadership team
Management profileNumber of profiles
Profiles8 records
Resolve BioSciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Resolve BioSciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Resolve BioSciences
What does Resolve BioSciences do?
Resolve BioSciences delivers a Molecular Cartography™ spatial biology platform built on single-molecule fluorescence in situ hybridization (smFISH), enabling high-resolution, multi-modal profiling of RNA (up to 330 targets), protein (10+ markers), and H&E morphology on the same tissue section without tissue clearing or signal amplification. Offerings include the MC1 and MC2 benchtop instruments, RNA and protein assays, deep learning–based cell segmentation, the ReCognize cloud-based 3D visualization application, and the Panel Design Studio for custom gene panel creation. The company provides these capabilities primarily as fee-for-service spatial biology analysis and through subscription access to its software tools for life sciences researchers and pharmaceutical developers.
Is Resolve BioSciences a public or private company?
Resolve BioSciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Resolve BioSciences founded?
Resolve BioSciences was founded in 2020. It employs 51 to 100 people.
Where is Resolve BioSciences based?
Resolve BioSciences is headquartered in Düsseldorf, Germany, in the Europe region.
How does Resolve BioSciences make money?
Two revenue lines are on record. Molecular Cartography Platform Services are the primary driver. The others are software and Data Analysis Tools.
Who are Resolve BioSciences's main competitors?
Direct peers on record are 10x Genomics, NanoString Technologies, Vizgen and Akoya Biosciences. Emerging players are Rebus Biosystems and Singular Genomics. Broad incumbents are Bio-Techne, Bruker, Standard BioTools and Illumina.
Does Resolve BioSciences have an API?
No public API is recorded for Resolve BioSciences.
What industry is Resolve BioSciences in?
Resolve BioSciences's product category is Spatial Biology / Spatial Transcriptomics. Its primary akta.pro industry code is HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 541714 and its SIC code is 3826.